A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection

Launched by R W JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE · Aug 30, 2001

Keywords

ClinConnect Summary

No description provided

Gender

MALE

Eligibility criteria

• • Inclusion Criteria
• Patients must have the following:
• • HIV infection.
• • Exclusion Criteria
• Co-existing Condition:
• Patients with the following symptoms or conditions are excluded:
• • Active opportunistic infection or neoplasm.
• • High likelihood of death during study.
• • Significant ophthalmologic, renal, hepatic, cardiovascular, hematologic, neurologic, psychiatric,respiratory, or metabolic disease.
• • Donation of \> 1 unit blood or acute loss of blood within one month of study entry.
• Patients with the following prior conditions are excluded:
• • History of opportunistic infection.
• • Previous allergic reaction to ciprofloxacin, norfloxacin, or any other quinolone.
• Prior Medication:
• Excluded:
• • Use of any investigational agent within 7 days of entry into study. Use of any medication within 3 days prior to entry (7 days for AZT). Alcohol or drug abuse.